Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet Infect Dis. 2005 Jun;5(6):374-82.

Management of patients co-infected with hepatitis B virus and HIV.

Author information

  • 1Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain. m_nunez_g@hotmail.com

Abstract

The management of chronic hepatitis B virus (HBV) infection poses specific problems in the presence of HIV co-infection, since therapeutic approaches have to consider both HBV and HIV infections. There are currently four drugs approved for the treatment of chronic HBV infection (interferon alpha, lamivudine, adefovir, and entecavir); the dual antiviral activity of tenofovir and emtricitabine broadens the armamentarium against HBV in HBV/HIV co-infected patients. Nucleotide analogues--eg, adefovir and tenofovir--have the advantage of a higher genetic barrier to the development of resistance compared with nucleoside analogues--eg, lamivudine and emtricitabine. Fortunately, the two families do not share resistance mutations, allowing salvage therapy and the possibility of combination therapy for drug-naive individuals. Although response to interferon alpha is poorer in HBV/HIV co-infected patients compared with HIV-negative individuals, especially in hepatitis B e antigen-negative HBV infection, the more potent pegylated forms of interferon alpha have brought new hope.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk